OptiKira Pursuing A Novel Small-Molecule Approach To Retinitis Pigmentosa

Retinitis pigmentosa is the leading cause of inherited blindness, and the early-stage US biotech OptiKira LLC is one of a dozen or so companies evaluating novel treatment approaches to the condition.

But OptiKira is unusual in that it is researching small-molecule inhibitors for a disease that has attracted widespread interest from companies developing cell and gene therapies – cells and genes can be administered directly into the eye, reducing potential systemic adverse